HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers
The presence of anti-human leucocyte antigen (HLA) antibodies in the potential solid organ transplant recipient’s blood is one of the main barriers to access to a transplantation. The HLA sensitization is associated with longer waitlist time, antibody mediated rejection and transplant lost leading t...
Main Authors: | Nizar Joher, Marie Matignon, Philippe Grimbert |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.688301/full |
Similar Items
-
Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
by: Torben Plesner, et al.
Published: (2020-02-01) -
CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
by: Dario Roccatello, et al.
Published: (2020-06-01) -
Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies
by: Guido Lancman, et al.
Published: (2018-11-01) -
The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
by: Eleonora Calabretta, et al.
Published: (2020-03-01) -
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
by: Ilaria Saltarella, et al.
Published: (2020-01-01)